Showing results (201-210 of 223) with videos related to
Sort By:
Pageof 23
BMJ Open|February 10, 2024
Cohort profile: PRESTIGIO, an Italian prospective registry-based cohort of people with HIV-1 resistant to reverse transcriptase, protease and integrase inhibitorsTommaso Clemente, Laura Galli, Riccardo Lolatto, et al.Journal of Infection and Public Health|June 22, 2023
Outcome of patients with carbapenem-resistant Acinetobacter baumannii infections treated with cefiderocol: A multicenter observational studyFederica Calò, Lorenzo Onorato, Ilaria De Luca, et al.International Journal of Environmental Research and Public Health|March 11, 2023
Healthcare Resource Consumption and Related Costs in Patients on Antiretroviral Therapies: Findings from Real-World Data in ItalyValentina Perrone, Melania Dovizio, Diego Sangiorgi, et al.Antiviral Therapy|April 22, 2020
DAA-based treatment for HIV-HCV-coinfected patients: analysis of factors of sustained virological response in a real-life studyLoredana Alessio, Lorenzo Onorato, Vincenzo Sangiovanni, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|January 25, 2020
Brief Report: Virologic Response by Baseline Viral Load With Dolutegravir Plus Lamivudine vs Dolutegravir Plus Tenofovir Disoproxil Fumarate/Emtricitabine: Pooled AnalysisJoseph Eron, Chien-Ching Hung, Jean-Guy Baril, et al.Antiviral Therapy|September 17, 2013
Durability of lopinavir/ritonavir monotherapy in individuals with viral load ≤50 copies/ml in an observational settingAntonella d'Arminio Monforte, Nicola Gianotti, Alessandro Cozzi-Lepri, et al.Antimicrobial Agents and Chemotherapy|January 7, 2009
Treatment with the fusion inhibitor enfuvirtide influences the appearance of mutations in the human immunodeficiency virus type 1 regulatory protein revValentina Svicher, Claudia Alteri, Roberta D'Arrigo, et al.The Journal of Antimicrobial Chemotherapy|October 13, 2019
Impact of NRTI resistance mutations on virological effectiveness of antiretroviral regimens containing elvitegravir: a multi-cohort studySara Modica, David Redi, Roberta Gagliardini, et al.The Lancet. HIV|June 7, 2020
Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trialsChloe Orkin, Edwin DeJesus, Paul E Sax, et al.Journal of Viral Hepatitis|December 11, 2020
High rates of sustained virological response despite premature discontinuation of directly acting antivirals in HCV-infected patients treated in a real-life settingMassimiliano Fabbiani, Andrea Lombardi, Marta Colaneri, et al.Pageof 23